These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6177415)

  • 1. High-dose medroxyprogesterone acetate for the treatment of advanced ovarian carcinoma.
    Tropé C; Johnsson JE; Sigurdsson K; Simonsen E
    Cancer Treat Rep; 1982 Jun; 66(6):1441-3. PubMed ID: 6177415
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
    Aabo K; Pedersen AG; Haid I; Dombernowsky P
    Cancer Treat Rep; 1982 Feb; 66(2):407-8. PubMed ID: 6459846
    [No Abstract]   [Full Text] [Related]  

  • 3. An overview of clinical trials with high-dose medroxyprogesterone acetate (HD-MPA) in endocrine-related tumors other than breast cancer.
    Robustelli della Cuna G; Zanon P; Pavesi L; Preti P; Prada GA; Decensi A
    Chemioterapia; 1986 Jun; 5(3):164-72. PubMed ID: 2941173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of high doses of medroxyprogesterone acetate in the palliative treatment of advanced breast cancer. Clinical experience with 44 cases].
    Amadori D; Ravaioli A; Barbanti F
    Minerva Med; 1977 Dec; 68(59):3967-80. PubMed ID: 74811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone in the management of hormone-dependent inoperable tumours.
    Szemesi I
    Ther Hung; 1972; 20(4):150-1. PubMed ID: 4135097
    [No Abstract]   [Full Text] [Related]  

  • 7. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
    Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
    Hamerlynck JV; Maskens AP; Mangioni C; van der Burg ME; Wils JA; Vermorken JB; Rotmensz N
    Gynecol Oncol; 1985 Nov; 22(3):313-6. PubMed ID: 2998957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal therapy of renal cell carcinoma (RCC).
    Bracci U; DiSilverio F; Concolino G
    Prog Clin Biol Res; 1982; 100():623-40. PubMed ID: 7145993
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
    Brubaker LH; Troner MB; Birch R
    Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Megestrol acetate for the palliation of advanced ovarian carcinoma.
    Geisler HE
    Obstet Gynecol; 1983 Jan; 61(1):95-8. PubMed ID: 6185891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
    Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
    Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tolerance and clinical effects of ethynodiol diacetate in massive doses (50 to 100 mg per day) in treatment of advanced uterine and ovarian cancer (10 cases of advanced cancer)].
    Soutoul JH; Jabot C; Gallier J; Bertrand J
    Bull Fed Soc Gynecol Obstet Lang Fr; 1969; 21(1):80-2. PubMed ID: 5383890
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
    Long HJ; Nelimark RA; Su JQ; Garneau SC; Levitt R; Goldberg RM; Poon MA; Kugler JW
    Gynecol Oncol; 1994 Aug; 54(2):180-3. PubMed ID: 8063243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
    Senn HJ; Lei D; Castaño-Almendral A; Brunner KW; Martz G; Obrecht P; Melchert F; Rhomberg W
    Schweiz Med Wochenschr; 1980 Aug; 110(33):1202-8. PubMed ID: 7423163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.